NasdaqGS:PODDMedical Equipment
Assessing Insulet (PODD) Valuation After Omnipod 5 Global Expansion and FDA Win for Type 2 Diabetes
If you’ve been following Insulet (PODD) lately, you’ll know there’s plenty of buzz around the stock. The surge in Insulet’s share price has been driven by three impactful events: its Omnipod 5 system secured FDA clearance for type 2 diabetes, the company launched this system in new international markets, and it also introduced Omnipod Discover, a digital platform aimed at further improving patient engagement. For those wondering why Insulet keeps hitting new highs, these moves demonstrate how...